Climb Bio reported Phase 1 data for anti-APRIL antibody CLYM116 demonstrating a ~29-day half-life and >90% APRIL suppression, supporting every-12-week dosing. The company expects initial NAVIGATE-2 data in H1 2027.
Climb Bio reported Phase 1 data for anti-APRIL antibody CLYM116 demonstrating a ~29-day half-life and >90% APRIL suppression, supporting every-12-week dosing. The company expects initial NAVIGATE-2 data in H1 2027.